PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany.\', \'Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.\', \'Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland.\', \'YUMAB GmbH, Braunschweig, Germany.\', \'Technische Universität Braunschweig, Institut für Genetik, Braunschweig, Germany.\', \'BioCopy GmbH, Emmendingen, Germany.\', \'Helmholtz Centre for Infection Research, Research Group Innate Immunity and Infection, Braunschweig, Germany.\', \'Westfälische Wilhelms-Universität Münster, Institut für Virologie (IVM), Münster, Germany.\', \'Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland. luca.varani@irb.usi.ch.\', \'BioCopy GmbH, Emmendingen, Germany. guenter.roth@biocopy.de.\', \'Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. Luka.Cicin-Sain@helmholtz-hzi.de.\', \'Centre for Individualised Infection Medicine (CIIM), a joint venture of Helmholtz Centre for Infection Research and Medical School Hannover, Braunschweig, Germany. Luka.Cicin-Sain@helmholtz-hzi.de.\', \'Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany. maren.schubert@tu-bs.de.\', \'Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany. m.hust@tu-bs.de.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-021-21609-2
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 33707427
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33707427>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33707427>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all